Talis Biomedical reports Q4 results
- Talis Biomedical press release (NASDAQ:TLIS): Q4 Revenue of $0.26M (-69.8% Y/Y) misses by $0.52M.
- Net loss was $26.9 million for the fourth quarter of 2022, compared to $28.7 million for the same period in 2021.
- Shares -3.31% AH.